GNH USA

Europe — EMA

Meriofert

GNH USA supplies Meriofert (Luteinising Hormone, Follicle‑Stimulating Hormone), a gonadotropin for infertility due to anovulation and ART protocols.

Luteinising Hormone (Human), Follicle-Stimulating Hormone

Request sourcing

1
Pack/s

What is Luteinising Hormone (Human), Follicle-Stimulating Hormone?

Luteinising hormone (human), Follicle‑stimulating hormone, the active ingredient in Meriofert, is a gonadotropin presented as a sterile injectable for intramuscular, subcutaneous use. It is used to stimulate ovarian follicular development in women with infertility due to anovulation and in assisted reproductive technology protocols.

GNH USA supplies Meriofert as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, fertility clinics and pharmacies worldwide.

What is Luteinising Hormone (Human), Follicle-Stimulating Hormone used for?

Meriofert, a gonadotropin used in reproductive endocrinology, is indicated for the following conditions:

- Infertility due to anovulation: supports follicular growth and ovulation in women who do not ovulate spontaneously. - Assisted reproductive technology (ART) protocols: provides controlled ovarian stimulation for in‑vitro fertilisation cycles. - Controlled ovarian hyperstimulation for IVF: enhances multiple follicle development to increase oocyte retrieval.

What are the side effects of Luteinising Hormone (Human), Follicle-Stimulating Hormone?

Meriofert may cause a range of adverse reactions. Monitoring and prompt reporting are recommended.

Common Side Effects: - Injection site pain or erythema. - Mild abdominal discomfort. - Headache. - Nausea. - Transient swelling of ovaries.

Serious or Rare Side Effects: - Ovarian hyperstimulation syndrome (OHSS). - Multiple pregnancy. - Severe allergic reaction (anaphylaxis). - Ectopic pregnancy. - Thromboembolic events.

What precautions apply to Luteinising Hormone (Human), Follicle-Stimulating Hormone?

When using Meriofert, consider the following precautions:

- Monitor ovarian response: perform serial ultrasound and estradiol measurements. - Assess OHSS risk: limit dose in patients with polycystic ovary syndrome or high baseline estradiol. - Avoid in hormone‑dependent tumors: contraindicated due to potential stimulation. - Use caution with thyroid disease: adjust concomitant thyroid medication as needed. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

What does Luteinising Hormone (Human), Follicle-Stimulating Hormone interact with?

Potential drug interactions with Meriofert should be evaluated before therapy.

Major Interactions (Avoid): - GnRH antagonists: may blunt the intended ovarian response. - Oral contraceptives: suppress endogenous gonadotropins, reducing efficacy. - High‑dose estrogen therapy: can interfere with follicular development.

Moderate Interactions (Monitor Closely): - Thyroid hormone replacement: may require dose adjustment during stimulation. - Glucocorticoids: can affect ovarian response, monitor estradiol levels. - Anticoagulants: observe for bleeding at injection sites.

Frequently asked questions

What is Meriofert used for?+
Meriofert is a gonadotropin preparation containing human luteinising hormone and follicle‑stimulating hormone. It is used to induce follicular development and ovulation in women with infertility due to anovulation and to support controlled ovarian stimulation in assisted reproductive technology cycles such as in‑vitro fertilisation.
How does luteinising hormone and follicle‑stimulating hormone work in Meriofert?+
The hormones in Meriofert bind to LH and FSH receptors on ovarian cells, activating intracellular cyclic AMP signaling. This promotes the growth and maturation of ovarian follicles, increases estradiol production, and triggers the ovulatory surge necessary for the release of a mature oocyte.
What is the usual dose of Meriofert?+
The dose of Meriofert is individualized. A qualified prescriber determines the amount, frequency, and duration based on the patient’s ovarian response, treatment protocol, and clinical goals. Dosing regimens are not standardized and should follow the prescribing physician’s instructions.
Is Meriofert safe to use during pregnancy or breastfeeding?+
Meriofert is intended for use before conception to facilitate ovulation. Its safety in established pregnancy or while breastfeeding has not been established, and it is generally not recommended for use during these periods. Consultation with a healthcare professional is essential.
How do I order Meriofert from GNH USA?+
To order Meriofert, submit an enquiry on the product page at gnh-usa.com specifying the required quantity. GNH USA works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required), and necessary import documentation.
How does Meriofert compare with other fertility drugs?+
Meriofert combines both LH and FSH activity, whereas some alternatives provide only FSH (e.g., recombinant FSH) or only LH. The dual activity can more closely mimic natural ovarian stimulation, potentially reducing the need for separate LH supplementation in certain protocols.
What are the storage and handling requirements for Meriofert?+
Meriofert should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. Keep it in the original packaging until use and allow the solution to reach room temperature before administration, following aseptic technique.
How is Meriofert administered?+
Meriofert is supplied as a sterile injectable solution for intramuscular or subcutaneous injection. Administration is performed by a qualified healthcare professional using aseptic technique, typically in the thigh, buttock, or abdominal wall, according to the prescribed dosing schedule.
What are the most serious risks associated with Meriofert?+
The most serious risks include ovarian hyperstimulation syndrome (OHSS), which can be severe and require hospitalization, multiple pregnancy, severe allergic reactions such as anaphylaxis, and rare thromboembolic events. Patients should be monitored closely for early signs of these complications.
Who should not use Meriofert?+
Meriofert is contraindicated in patients with known hypersensitivity to human gonadotropins, active hormone‑dependent malignancies, uncontrolled thyroid disease, or severe ovarian cysts. It should also be avoided in women who are already pregnant or breastfeeding.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Luteinising Hormone (Human), Follicle-Stimulating Hormone
Route
Intramuscular Use , Subcutaneous Use
Manufacturer
Ibsa Farmaceutici Italia
Origin
EU

Related products

A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU